Pharmacokinetics of rifampin and isoniazid in tuberculosis-hivcoinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3182-3190

  Bhatt, N B ^a,b   Barau, C ^c   Amin, A ^c   Baudin, E ^d   Meggi, B ^a   Silva, C ^d   Furlan, V ^c   Grinsztejn, B ^b   Barrail Tran, A ^c,e   Bonnet, M ^d   Taburet, A M ^c  

^a INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^b Funda??o Oswaldo Cruz   (Brazil)

^c BICÊTRE HOSPITAL   (France)

^d EPICENTRE   (France)

^e EA4123   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; PYRAZINAMIDE; RIFAMPICIN; BENZOXAZINE DERIVATIVE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MORNING DOSAGE; MOZAMBIQUE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEADY STATE; COMPLICATION; CONTROLLED STUDY; HALF LIFE TIME; HIV INFECTIONS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; BENZOXAZINES; COINFECTION; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84901255916     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02379-13     Document Type: Article

References (51)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/ global-report/en/.
2. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. 2010. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362:697-706. http://dx.doi.org/10.1056/ NEJMoa0905848.
3. World Health Organization. 2010. Guidelines for treatment of tuberculosis, fourth edition. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/2010/9789241547833/en/index.html.
4. Barry C, Waring J, Stapledon R, Konstantinos A, National Tuberculosis Advisory Committee, for the Communicable Diseases Network Australia. 2012. Tuberculosis notifications in Australia, 2008 and 2009. Commun. Dis. Intell. Q. Rep. 36:82-94.
5. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495-200262150- 00001.
6. Iseman MD. 2002. Tuberculosis therapy: past, present and future. Eur. Respir. J. Suppl. 36:87s-94s. http://dx.doi.org/10.1183/09031936.02.00309102.
7. Sanchez M, Bartholomay P, Arakaki-Sanchez D, Enarson D, Bissell K, Barreira D, Harries A, Kritski A. 2012. Outcomes of TB treatment by HIV status in national recording systems in Brazil, 2003-2008. PLoS One 7:e33129. http://dx.doi.org/10.1371/journal.pone.0033129.
8. Ismail I, Bulgiba A. 2013. Determinants of unsuccessful tuberculosis treatment outcomes in Malaysian HIV-infected patients. Prev. Med. 57(Suppl):S27-S30. http://dx.doi.org/10.1016/j.ypmed.2012.12.023.
9. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694. http://dx.doi.org/10.1086/599040.
10. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177. http://dx.doi.org/10.1128/AAC.50.4.1170-1177.2006.
11. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48:4473-4475. http://dx.doi.org/10.1128/AAC.48.11.4473-4475.2004.
12. Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I, Oliveras L, Walker S, Rachlis A, Cameron DW. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293. http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00006.
13. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, Rida W, Pym A, Smith PJ, Onyebujoh PC. 2012. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob. Agents Chemother. 56:3232-3238. http://dx.doi.org/10.1128/AAC.05526-11.
14. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. World Health Organization, Geneva, Switzerland. http://www.who.int/ hiv/pub/arv/adult2010/en/index.html.
15. Rakhmanina NY, van den Anker JN. 2010. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6:95-103. http://dx.doi.org/10. 1517/17425250903483207.
16. Back D, Gibbons S, Khoo S. 2003. Pharmacokinetic drug interactions with nevirapine. J. Acquir. Immune Defic. Syndr. 34(Suppl 1):S8-S14.
17. Dickinson JM, Aber VR, Mitchison DA. 1977. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 116:627-635.
18. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. 1985. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63:1205-1211. http://dx.doi.org/10.1007/ BF01733779.
19. Tirona RG, Leake BF, Wolkoff AW, Kim RB. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304:223-228. http://dx.doi.org/10.1124/jpet.102.043026.
20. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2011. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br. J. Clin. Pharmacol. 72:51-62. http://dx.doi.org/10.1111/j.1365-2125.2011.03940.x.
21. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD. 2003. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930. http://dx.doi.org/10.1053/jhep. 2003.50144.
22. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Venkatesan P, Sekar L, Kumar S, Krishnarajasekhar OR, Paramesh P. 2004. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 38:280-283. http://dx.doi.org/10.1086/380795.
23. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE. 2009. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 29:503-510. http://dx.doi.org/10.1592/phco.29. 5.503.
24. van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso H, van der Meer JW, Burger D, Nelwan RH. 2002. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int. J. Tuberc. Lung Dis. 6:497-502. http://dx.doi.org/10.0000/09640569513002.
25. Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A. 2013. Nevirapine versus efavirenz for patients coinfected with HIV and tuberculosis: a randomised noninferiority trial. Lancet Infect. Dis. 13:303-312. http://dx.doi.org/10.1016/ S1473-3099(13)70007-0.
26. Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinzstejn B, Barrail-Tran A, Bonnet M, Taburet AM, ANRS 12146-CARINEMO Study Group. 2012. Pharmacokinetics of rifampicin and isoniazid in TB-HIV co-infected patients on nevirapine-or efavirenzbased antiretroviral treatment (ANRS12214), p S82, abstr OP-119-15. Abstr. 43rd Conference of the International Union Against Tuberculosis and Lung Diseases (IUATLD).
27. Aparicio I, Bello MA, Callejon M, Guiraum A. 2006. Simultaneous determination of rifampicin and sulbactam in mouse plasma by highperformance liquid chromatography. Biomed. Chromatogr. 20:748-752. http://dx.doi.org/10. 1002/bmc.591.
28. Miscoria G, Leneveu A, Walle C, Roux A. 1988. Application of a method of analysis using high performance liquid chromatography of isoniazid\ and acetylisoniazid to determine the phenotype of acetylation. Ann. Biol. Clin. 46:734-740. (In French.
29. Titier K, Lagrange F, Pehourcq F, Edno-Mcheik L, Moore N, Molimard M. 2002. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two nonnucleoside reverse transcriptase inhibitors in human plasma. Ther. Drug Monit. 24:417-424. http://dx.doi.org/10.1097/00007691-200206000-00015.
30. Berning SE, Huitt GA, Iseman MD, Peloquin CA. 1992. Malabsorption of antituberculosis medications by a patient with AIDS. N. Engl. J. Med. 327:1817-1818. http://dx.doi.org/10.1056/NEJM199212173272514.
31. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788. http://dx.doi.org/10.1128/AAC.01533-06.
32. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51:2329-2336. http://dx.doi.org/10. 1128/AAC.00185-07.
33. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA. 2005. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41:1638-1647. http://dx.doi.org/10.1086/498024.
34. Peloquin CA, Namdar R, Dodge AA, Nix DE. 1999. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int. J. Tuberc. Lung Dis. 3:703-710.
35. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18. http://dx.doi.org/10.1378/chest.115.1.12.
36. Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE. 2013. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob. Agents Chemother. 57: 3208-3213. http://dx.doi.org/10.1128/AAC.02599-12.
37. Peloquin CA. 1998. Serum concentrations of the antimycobacterial drugs. Chest 113:1154-1155. http://dx.doi.org/10.1378/chest.113.5.1154.
38. Barroso EC, Pinheiro VG, Facanha MC, Carvalho MR, Moura ME, Campelo CL, Peloquin CA, Guerrant RL, Lima AA. 2009. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am. J. Trop. Med. Hyg. 81:322-329.
39. Koegelenberg CF, Nortje A, Lalla U, Enslin A, Irusen EM, Rosenkranz B, Seifart HI, Bolliger CT. 2013. The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care. S. Afr. Med. J. 103:394-398. http://dx.doi.org/10.7196/samj.6344.
40. Singla R, Srinath D, Gupta S, Visalakshi P, Khalid UK, Singla N, Gupta UA, Bharty SK, Behera D. 2009. Risk factors for new pulmonary tuberculosis patients failing treatment under the Revised National Tuberculosis Control Programme, India. Int. J. Tuberc. Lung Dis. 13:521-526.
41. Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Farnia P, Marjani M, Shamai M, Amiri M, Nikaein S, Mansouri D, Masjedi M, Altice F. 2012. Treatment outcome, mortality and their predictors among HIVassociated tuberculosis patients. Int. J. STD AIDS 23:e1-e4. http://dx.doi.org/10.1258/ijsa.2009.009093.
42. Shaheen A, Najmi MH, Saeed W, Farooqi ZU. 2012. Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan. Scand. J. Infect. Dis. 44:459-464. http://dx.doi.org/10.3109/00365548. 2011.647832.
43. Hoa NB, Lauritsen JM, Rieder HL. 2013. Changes in body weight and tuberculosis treatment outcome in Viet Nam. Int. J. Tuberc. Lung Dis. 17:61-66. http://dx.doi.org/10.5588/ijtld.12.0369.
44. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, Kim SJ, Jindani A, Enarson DA, Nunn AJ. 2011. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 305:1415-1423. http://dx.doi.org/10.1001/jama.2011.436.
45. World Health Organization. 2013. World Health Organization Consolidated guidelines on the use of antiretriviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/guidelines/ arv2013/download/en/index.html.
46. Jain A, Mehta VL, Kulshrestha S. 1993. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber. Lung Dis. 74:87-90. http://dx.doi.org/10.1016/0962-8479(93)90032-S.
47. Saleri N, Dembele SM, Villani P, Carvalho AC, Cusato M, Bonkoungou V, Nacanabo R, Kouanda S, Comelli M, Regazzi M, Matteelli A. 2012. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. J. Antimicrob. Chemother. 67:469-472. http://dx.doi.org/10.1093/jac/dkr445.
48. Shenfield GM. 2004. Genetic polymorphisms, drug metabolism and drug concentrations. Clin. Biochem. Rev. 25:203-206.
49. O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. 1997. N-Acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin. Pharmacol. Ther. 62:261-271. http://dx.doi.org/10. 1016/S0009-9236(97)90028-X.
50. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. 2010. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54:4192-4200. http://dx.doi.org/10.1128/AAC.00353- 10.
51. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. http://dx.doi.org/10.1128/AAC.00461-07. Virales